Arbutus Biopharma (ABUS) vs BlossomHill Therapeutics (BLSM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Arbutus Biopharma is the larger company by market cap ($646.8 million vs $555.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABUS | BLSM |
|---|---|---|
| Share price | $4.22 | $17.48 |
| Market cap | $646.82M | $555.60M |
| 1-day change | +0.96% | +3.55% |
| YTD return | -12.27% | — |
| 1-year return | -1.17% | — |
| 5-year return | +2.45% | — |
| P/E ratio (TTM) | 5.27 | — |
| EPS (TTM) | $0.80 | $-4.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.45 | $27.99 |
| 52-week low | $3.50 | $15.25 |
| Distance from 52-week high | -22.57% | -37.55% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +26.78% | +102.52% |
| Average volume | 4.74M | 261.23K |
| Shares outstanding | 153.28M | 31.78M |
| Employees | 19 | 69 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Arbutus Biopharma
ABUS stock →Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
About BlossomHill Therapeutics
BLSM stock →BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS).
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
ABUS vs BLSM FAQ
Which is bigger, Arbutus Biopharma or BlossomHill Therapeutics?
Arbutus Biopharma (ABUS) is larger, with a market capitalization of $646.82M compared with $555.60M for BlossomHill Therapeutics (BLSM).
Are Arbutus Biopharma and BlossomHill Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.